© 2006 European Society for Medical Oncology
review |
Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?
1 Department of Medical Oncology and 2 Department of Nuclear Medicine, Antwerp University Hospital, Belgium
* Correspondence to: Dr T. Van den Wyngaert, Antwerp University Hospital, Department of Medical Oncology, Wilrijkstraat 10, 2650 Edegem, Belgium. Tel: +32-473-542124; Fax: +32-3-8253308; E-mail: tim.van.den.wyngaert{at}skynet.be
Background: An increasing amount of reports are being published suggesting a relationship between the use of bisphosphonates (BPs) and the development of osteonecrosis of the jaw (ONJ). We reviewed the currently available evidence and explore the potential mechanisms of action based on the known effects of the concerned BP.
Design: The MEDLine, Current Contents and Science Citation Index Expanded databases were queried and the results augmented by analyzing cited references and recent congress proceedings.
Results: 22 papers were included detailing 225 patients, all based on retrospective chart review without control groups. The prevalence of ONJ was estimated at 1.5%. The involved BPs were pamidronate, zoledronic acid, alendronate and risedronate, all potent nitrogen-containing agents. The most common symptom was pain (81.7%), although 12.2% of cases were asymptomatic. In 69.3% of patients ONJ was preceded by a dental extraction. At the time of diagnosis, 74.5% of patients were receiving chemotherapy and in 38.2% of cases corticosteroids were administered. Although various conservative and surgical treatment modalities were reported, residual sites of ONJ persisted in 72.5% of cases.
Conclusion: Although not enough evidence is available to prove a causal link, it seems that under specific circumstances local defenses can become overwhelmed resulting in ONJ.
Key words: bisphosphonates, jaw, osteonecrosis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Zuradelli, G. Masci, G. Biancofiore, G. Gullo, M. Scorsetti, P. Navarria, F. Tancioni, M. Berlusconi, L. Giordano, and A. Santoro High Incidence of Hypocalcemia and Serum Creatinine Increase in Patients with Bone Metastases Treated with Zoledronic Acid Oncologist, May 1, 2009; 14(5): 548 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Van den Wyngaert, T. Claeys, M. T. Huizing, J. B. Vermorken, and E. Fossion Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome Ann. Onc., February 1, 2009; 20(2): 331 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Van den Wyngaert, M. T. Huizing, E. Fossion, and J. B. Vermorken Bisphosphonates in Oncology: Rising Stars or Fallen Heroes Oncologist, February 1, 2009; 14(2): 181 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pazianas, R. G. G. Russell, and I. Fogelman Osteonecrosis of the Jaw: More Heat Than Light J. Nucl. Med., January 1, 2009; 50(1): 6 - 7. [Full Text] [PDF]
|
|
|
|
 |
|
 T. B. Dodson, N. S. Raje, P. A. Caruso, and A. E. Rosenberg Case 9-2008 -- A 65-Year-Old Woman with a Nonhealing Ulcer of the Jaw N. Engl. J. Med., March 20, 2008; 358(12): 1283 - 1291. [Full Text] [PDF]
|
|
|
|
|
|
M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann. Onc., March 1, 2008; 19(3): 420 - 432. [Abstract] [Full Text] [PDF]
|
|
E-letters:
Read all E-letters
- Bisphosphonates and Osteonecrosis of the jaws (ONJ) : claiming risk factor studies
- Vittorio Fusco, et al.
- Annals of Oncology, 10 Oct 2006 [Full text]